Search Within

Isabelle C Riviere

  1. "Xiuyan Wang"
  2. "Biostatistics Service"
Formats
  1. Journal Article (12)
  2. Meeting Abstract (5)
  3. Research Letter (1)
Groups
  1. Biostatistics Service (18)
  2. Center for Hematologic Malignancies (18)
  3. Department of Medicine (18)
  4. Epidemiology and Biostatistics (18)
  5. Hematologic Malignancies Research (18)
  6. Hematologic Malignancies, Division of (18)

More Groups

People
  1. Xiuyan Wang (18)
  2. Michel Sadelain (16)
  3. Jae Park (15)
  4. Renier Brentjens (15)
  5. Brigitte Senechal (12)
  6. Elizabeth Halton (10)

More People

Years
  1. 2022 (1)
  2. 2021 (4)
  3. 2019 (5)
  4. 2018 (3)
  5. 2017 (1)
  6. 2014 (2)

More Years

Publications
  1. Blood (7)
  2. Cancer Discovery (2)
  3. Molecular Therapy (2)
  4. New England Journal of Medicine (2)
  5. Hematological Oncology (1)
  6. JCI Insight (1)

More Publications

Publishers
  1. American Society of Hematology (7)
  2. Nature Publishing Group (3)
  3. American Association for Cancer Research (2)
  4. Massachusetts Medical Society (2)
  5. Amer Soc Clinical Investigation Inc (1)
  6. American Association for the Advancement of Science (1)

More Publishers

Results (18)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab
    Journal Article

    Adusumilli, P. S.; Zauderer, M. G.; Rivière, I.; Solomon, S. B.; Rusch, V. W.; O'Cearbhaill, R. E.; Zhu, A.; Cheema, W.; Chintala, N. K.; Halton, E.; more...
    Cancer Discovery (2021)

    Fulltext@MSK | Save
  • Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia
    Research Letter

    Perica, K.; Flynn, J.; Curran, K. J.; Rivere, I.; Wang, X.; Senechal, B.; Halton, E.; Diamonte, C.; Pineda, J.; Bernal, Y.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy
    Journal Article

    Wudhikarn, K.; Flynn, J. R.; Rivière, I.; Gönen, M.; Wang, X.; Senechal, B.; Curran, K. J.; Roshal, M.; Maslak, P. G.; Geyer, M. B.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical factors associated with improved survival following allogeneic HSCT after CD19 CAR therapy in adult patients with relapsed B-ALL
    Meeting Abstract

    Park, J. H.; Flynn, J.; Gonen, M.; Bernal, Y.; Diamonte, C.; Halton, E.; Wang, X.; Riviere, I.; Sadelain, M.; Brentjens, R. J.
    Blood (2019)

    Fulltext@MSK | Save
  • Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
    Journal Article

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Williams, D. A.; Shukla, N.; Kobos, R.; Forlenza, C. J.; Steinherz, P.; Prockop, S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL
    Meeting Abstract

    Perica, K.; Flynn, J.; Curran, K. J.; Wang, X.; Halton, E.; Diamonte, C.; Pineda, J.; Bernal, Y.; Gonen, M.; Riviere, I.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
    Journal Article

    Sauter, C. S.; Senechal, B.; Rivière, I.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Singh, A. N.; Szenes, V. Z.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL
    Journal Article

    Geyer, M. B.; Riviere, I.; Senechal, B.; Wang, X.; Wang, Y.; Purdon, T. J.; Hsu, M.; Devlin, S. M.; Palomba, M. L.; Halton, E.; more...
    JCI Insight (2019)

    Fulltext@MSK | Save